Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis
The Journal of Infectious Diseases · 23.09.2024 · 230 (3) · e536-e547
DOI: 10.1093/infdis/jiae051 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 05.03.2024. Verfasst von Emma L Ledger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas aeruginosa, Pseudomonas Infections, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, Common Good Prince Charles Hospital Foundation, Cystic Fibrosis Australia.
Abstract (Originalsprache)
Background
Pseudomonas aeruginosa is a multidrug-resistant pathogen causing recalcitrant pulmonary infections in people with cystic fibrosis (pwCF). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been developed that partially correct the defective chloride channel driving disease. Despite the many clinical benefits, studies in adults have demonstrated that while P. aeruginosa sputum load decreases, chronic infection persists. Here, we investigate how P. aeruginosa in pwCF may change in the altered lung environment after CFTR modulation.
Methods
P. aeruginosa strains (n = 105) were isolated from the sputum of 11 chronically colonized pwCF at baseline and up to 21 months posttreatment with elexacaftor-tezacaftor-ivacaftor or tezacaftor-ivacaftor. Phenotypic characterization and comparative genomics were performed.
Results
Clonal lineages of P. aeruginosa persisted after therapy, with no evidence of displacement by alternative strains. We identified commonly mutated genes among patient isolates that may be positively selected for in the CFTR-modulated lung. However, classic chronic P. aeruginosa phenotypes such as mucoid morphology were sustained, and isolates remained just as resistant to clinically relevant antibiotics.
Conclusions
Despite the clinical benefits of CFTR modulators, clonal lineages of P. aeruginosa persist that may prove just as difficult to manage in the future, especially in pwCF with advanced lung disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
- Northside Clinical Unit, The University of Queensland, Brisbane, Australia.
- Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia.
- Australian Infectious Diseases Research Centre, Brisbane, Australia.
- Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.
- QIMR Berghofer Medical Research Institute, Brisbane, Australia.
ORCID-Profile: Emma L Ledger, Jing Jie Teh, Mark Morrison, Timothy J Wells
Förderung
- Cystic Fibrosis Foundation
- Common Good Prince Charles Hospital Foundation
- Cystic Fibrosis Australia
Zitieren
APA
Ledger, E. L., Smith, D. J., Teh, J. J., Wood, M. E., Whibley, P. E., Morrison, M., Goldberg, J. B., Reid, D. W., & Wells, T. J. (2024). Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis. The Journal of Infectious Diseases, 230(3), e536-e547. https://doi.org/10.1093/infdis/jiae051
Vancouver
Ledger EL, Smith DJ, Teh JJ, Wood ME, Whibley PE, Morrison M, et al. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis. The Journal of Infectious Diseases. 2024;230(3):e536-e547. doi:10.1093/infdis/jiae051
BibTeX
@article{Ledger2024,
author = {Ledger, Emma L and Smith, Daniel J and Teh, Jing Jie and Wood, Michelle E and Whibley, Page E and Morrison, Mark and Goldberg, Joanna B and Reid, David W and Wells, Timothy J},
title = {Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {3},
pages = {e536--e547},
doi = {10.1093/infdis/jiae051}
}
EUVIMED